Drug updated on 4/30/2024
| Dosage Form | Injection (subcutaneous; 100 mg/mL) |
| Drug Class | Interleukin-23 blockers |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Indicated for the treatment of adult patients of active psoriatic arthritis.
Summary
- Guselkumab (Tremfya) is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis and active psoriatic arthritis, demonstrating significant improvements in Psoriasis Area and Severity Index (PASI) scores across various trials.
- A total of 18 systematic reviews/meta-analyses were reviewed to evaluate the safety and effectiveness of guselkumab compared to other drugs used for treating these conditions.
- Compared to IL-17 inhibitors such as ixekizumab, secukinumab, brodalumab, guselkumab often showed lower short-term PASI responses but was noted for its ability to reach PASI 90 outcomes with moderately high certainty.
- In comparison with Risankizumab, another IL-23 inhibitor, guselkumb was sometimes rated lower in terms of achieving PASI outcomes after one year; however it demonstrated better efficacy than some anti-TNFs particularly in nail psoriasis.
- For active psoriatic arthritis patients specifically, data suggests that Guselkamub's efficacy is comparable to IL -17A and subcutaneous TNF inhibitors regarding arthritis symptoms but offers superior skin outcome results.
- Racial or ethnic differences on drug efficacy were not extensively covered within the documents reviewed; however there are indications suggesting variations among different ethnic groups which necessitates further research.
- Guselakumb has a good safety profile similar to other biologics used for these conditions; common adverse events include nasopharyngitis upper respiratory tract infections injection site reactions headache diarrhea yet no significant difference from placebo group was observed concerning serious adverse events risk indicating an acceptable long term safety profile.
- In conclusion based on available evidence from systematic reviews meta analyses Guslekamb stands as a competitive option among biologic treatments especially considering long term management strategies due its favorable benefit-risk ratio.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tremfya (guselkumab) Prescribing Information. | 2023 | Janssen Biotech, Inc., Horsham, PA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Japanese guidance for use of biologics for psoriasis (the 2019 version). | 2019 | The Journal of Dermatology |
| Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. | 2019 | Journal of the American Academy of Dermatology |